MODIFIED BOTULINUM NEUROTOXIN FOR TREATING EXTREMITY SPASTICITY Russian patent published in 2025 - IPC A61K38/48 C12N9/52 A61P21/02 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and pharmaceutics. Objects 1 and 2 are methods for treating limb spasticity in an adult subject and children, including administration of modified botulinum neurotoxin A (BoNT/A) by intramuscular injection into multiple affected muscles of the subject, where modified BoNT/A is administered at a standard dose of 750 pg to 17.000 pg of modified BoNT/A in an adult subject and from 375 pg of up to 8.500 pg of modified BoNT/A in a child subject, into multiple affected muscles, and the modified BoNT/A contains the BoNT/A light chain and translocation domain, and the BoNT/B receptor-binding domain (HC domain). Objects 3–6 are standard dosage forms of modified botulinum neurotoxin A (BoNT/A) for treating extremity spasticity in an adult subject and children, as well as sets containing them. Objects 7 and 8 represent methods of treating extremity spasticity in an adult subject and children, involving administering a standard dosage form to the subject.

EFFECT: treatment of extremity spasticity with modified BoNT/A with introduction of a safe and effective standard dose, as well as a total dose that can be safely administered in a single treatment.

31 cl, 11 dwg, 15 tbl, 13 ex